Panelists stress that timely and accurate diagnosis of KMT2A-rearranged acute myeloid leukemia (AML) is essential for personalized treatment planning, highlighting the need to overcome systemic delays ...
Creating a synthetic control arm from previous clinical trials: Application to establishing early end points as indicators of overall survival in acute myeloid leukemia (AML). This is an ASCO Meeting ...
Panelists discuss how IDH inhibitors, particularly ivosidenib combined with azacitidine, represent potentially the greatest ...
Scientists at the University of Glasgow have successfully used the first bioengineered bone marrow model to carry out vital ...
Errata: Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis The classification of AML and therapeutic options are now largely driven ...
SAN DIEGO — A polygenic score can link outcomes in Black pediatric patients with acute myeloid leukemia (AML) to genetic traits that arise more frequently in this population, new data reveal. The ...
In October 2025, the U.S. Food and Drug Administration (FDA) granted approval to multiple new cancer therapies and supportive ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback